a bad liar trial is an industry
sponsored trial by the sea v r
x company they have originated some carotid
barrow stimulator technology that was previously evaluated
in the beat hf trial it has
now
achieved ft a approval and patients with
heart failure that is ah already optimized
on goal directed medical therapy with ongoing
symptoms i can be referred for implantation
of the device by the classic surgical
technique which includes a small incision on
the neck and placement of the device
at the carotid body
the bat wire trial utilizes the same
technology but the team has created a
percutaneous implantation system which is a modification
of assaulting her technique
this allows for ultrasound guidance and placement
up the device still over the carotid
body with the opportunity to verify that
location with stimulation
the opportunity for patients to have this
place percutaneous lee at this time does
not eliminate general anesthesia but we expect
that one of the advantages over the
long term will be the opportunity for
patients to have this placed outside of
the operating room setting
after implantation patients return for tight ration
of the device to their cardiology team
and that would be the same whether
the patient went through a standard commercial
device or if they were to participate
in the bat wire percutaneous implantation
however with the additional
consideration of the new implantation the after
year has also required some
additional ear nose and throat physician arm
evaluations following the trial to ensure safety
and thus far we have not seen
any patients with are significant injury during
the device placement
so one of the things that is
commonly asked about this study like doctor
ready as mentioned is kind of what
the future of this is as we
work to move this procedure from being
a procedure done under general anesthesia in
operating room to the type of procedure
that can be done similar to a
regular pacemaker to different
related implant potentially in a caf lab
or electrophysiology lab under moderate sedation
i think one of the other questions
that this comes into play with his
for getting a larger catchment audience for
this device as in the previous trials
with bgh f showed a great improvement
in quality of life overall great improvement
in six minute whole walks and other
signs
of clinical success as far as measurements
of heart failure that we deal with
i'm one of the possible limitations of
getting this out all the patients who
could potentially benefit from it is access
to a vascular surgeon was trained to
the plant this device was access to
a war time and under general anesthesia
i think as we move
move forward with getting this device out
to wider market and potentially moving it
into space where electro physiologist can implant
these devices hopefully we will get a
larger amount of patients that we can
help with this technology
i think around as we think about
treating patients with hard for
there's a gap that exists between medications
and medical therapy which is why say
and and in fact missing rule significant
responses what these therapies are and then
or therapies for can stay in hard
films include transplantation and winter to her
sister my son's
with there is a job for patients
who remain some march more on medications
that are not quite second off for
those therapies and i think that's where
this their preference or very wisely
my pension for example or was on
all the right therapies was to have
been on sometimes by was just not
quite ready for a transponder harp on
our and are particularly worse
the clinical trial it's been done on
this was a very much less aggressive
approach to put him in the device
and we've seen significant improvements in one
slightly good with two thousand two important
much more in our room to room
to treat or for
like a good song and something that
was in one more